A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

Ramesh K. Ramanathan,James L. Abbruzzese,Tomislav Dragovich,Lynn Kirkpatrick,Jose Guillen,Amanda F. Baker,Linda Pestano,Sylvan B. Green,Daniel D. Von Hoff

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

2011

Ramesh K. Ramanathan
James L. Abbruzzese
Tomislav Dragovich
Lynn Kirkpatrick
Jose Guillen
Amanda F. Baker
Linda Pestano
Sylvan B. Green
Daniel D. Von Hoff

Purpose This study evaluated PX-12, a novel small molecule inhibitor of the proto-oncogene (Trx-1), in patients with previously treated advanced pancreatic cancer (APC).

Keywords:

Pancreatic disease
Cancer
Cancer research
Thioredoxin
Progression-free survival
Pancreatic cancer
Pharmacology
Gemcitabine
Antimetabolite
Pathology
Medicine
Pancreas
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations